Express News | Bvf Partners LP Reports 8.2% Passive Stake in Verve Therapeutics Inc as of Nov 11 - SEC Filing

ReutersNov 18 17:31 ET

ARKK's Holdings Ranked by SA Quant Grades

Seeking AlphaNov 12 14:21 ET

CRISPR, Beam, Other Gene Editing Names up Significantly

Seeking AlphaNov 11 13:15 ET

RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17

Moomoo NewsNov 6 13:32 ET · Ratings

J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23

Moomoo NewsNov 6 13:32 ET · Ratings

CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32

Moomoo NewsNov 6 13:32 ET · Ratings